

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12Q 1/68</b>	<b>A2</b>	(11) International Publication Number: <b>WO 00/68424</b>  (43) International Publication Date: 16 November 2000 (16.11.00)
<p>(21) International Application Number: PCT/EP00/04591</p> <p>(22) International Filing Date: 4 May 2000 (04.05.00)</p> <p>(30) Priority Data: 60/132,705 5 May 1999 (05.05.99) US</p> <p>(71) Applicants (for all designated States except US): INSTITUT CURIE [FR/FR]; 26, rue d'Ulm, F-75248 Paris Cedex 05 (FR). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) [FR/FR]; 3, Rue Michel Ange, F-75794 Paris Cedex 16 (FR).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CAPPELLEN, David [FR/FR]; 8, avenue le Pont l'Evêque, F-14810 Merville-Franceville (FR). CHOPIN, Dominique [FR/FR]; 23, avenue de la Mame, F-94000 Creteil (FR). RAD-VANYI, François [FR/FR]; 36, rue des Potiers, F-92260 Fontenay-aux-Roses (FR). RICOL, David [FR/FR]; Bât. K, 40, rue Pascal, F-75013 Paris (FR). THIERY, Jean-Paul [FR/FR]; 16, rue Vandrezanne, F-75013 Paris (FR).</p> <p>(74) Agents: PEAUCELLE, Chantal et al.; Cabinet Armengaud Aîné, 3, avenue Bugeaud, F-75116 Paris (FR).</p>		<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: MEANS FOR DETECTING AND TREATING PATHOLOGIES LINKED TO FGFR3</p>		
<p>(57) Abstract</p> <p>The invention relates to a method for detecting carcinomas in a biological sample, comprising identifying FGFR3 mutations.</p>		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

### Means for detecting and treating pathologies linked to FGFR3.

5

The invention relates to means, i.e. method and drugs, for detecting and treating, respectively, pathologies linked to FGFR3 and/or to the FGFR3 pathway.

Fibroblast growth factor receptor 3 (FGFR3) belongs to a family of  
10 structurally related tyrosine kinase receptors (FGFRs 1-4) encoded by four different genes. These receptors are glycoproteins composed of two to three extracellular immunoglobulin (Ig)-like domains, a transmembrane domain and a split tyrosine-kinase domain. Alternative mRNA splicing results in many different receptors variants. Isoforms FGFR3-IIb and FGFR3-IIc result from a mutually exclusive splicing event in  
15 which the second half of the juxtamembrane Ig-like domain is encoded either by the 151 nucleotides long exon 8 (IIb variant) or the 145 nucleotides long exon 9 (IIc variant).

Specific point mutations in the *FGFR3* gene which affect different domains of the protein are associated with autosomal dominant human skeletal disorders such as hypochondroplasia, achondroplasia, severe achondroplasia with developmental  
20 delay and acanthosis nigricans and thanatophoric dysplasia. Several reports have demonstrated that these mutations lead to constitutive activation of the receptor. Taking into account this result, together with the skeletal overgrowth observed in mice homozygous for null alleles of *Fgfr3*, FGFR3 appears as a negative regulator of bone growth.

25 In contrast with this inhibitory role, an oncogenic role has been proposed for *FGFR3* in multiple myeloma (MM) development. In this malignant proliferation of plasma cells, a t(4;14)(p16.3;q32.3) chromosomal translocation with breakpoints located 50 to 100 Kb centromeric to *FGFR3* is present in 20-25% of the cases and is associated with overexpression of FGFR3.

30 In very rare cases (2 out of 12 MM cell lines and 1 out of 85 primary MM tumours), activating mutations of *FGFR3* previously identified in human skeletal disorders have been found, but always accompanied by the t(4;14)(p16.3;q32.3) translocation.

35 By investigating various cancers, the inventors have surprisingly found a role for FGFR3 in solid tumours, in particular in cancers originating from epithelial tissues, carcinomas.

The involvement of FGFR3 in such solid tumour development is linked to a constitutional activation : it may be activated by an autocrinal loop (ligand self-

production) and/or by activating mutations in *FGFR3*. Surprisingly, such mutations are found in primary tumours and are somatic mutations (genomic DNA mutations).

So far, the only *FGFR3* isoform which has been identified in epithelium is the *FGFR3-IIIb* isoform.

5           The invention thus relates to a method and kits for detecting such pathologies.

According to another aspect, the invention also relates to drugs capable of treating such pathologies.

10           According to still another aspect, it relates to transgenic animals enabling the efficiency of such drugs to be tested as well as to cell lines transfected with the different forms of *FGFR3* (useful *in vitro* and *in vivo*).

The method of the invention for detecting carcinomas in a biological sample comprises identifying *FGFR3* mutations.

15           Standard methods can apply for such an identification such as immunohistochemistry, or detection of the corresponding RNA, DNA, and encoded protein contained in said sample, particularly after extraction thereof. A common way for such a detection comprises amplifying by PCR, RT-PCR or RT-PCR SSCP (single strand conformation polymorphism) with *FGFR3* specific primers and revealing the amplification products according to the usual methods. A corresponding embodiment is exemplified in the examples given hereinafter. Another common way comprises the use of antibodies and the detection of the antigen-antibody reaction with appropriate labelling.

20           The activating function of a mutation can be determined by observation of activating signals such as receptor phosphorylation, cell proliferation (e.g. thymidine incorporation) or indirect effects such as calcium influx, phosphorylation of target sequences.

More particularly, said identification comprises screening for single nucleotide mutation(s) in the genomic DNA and/or its products, i.e. RNA, protein, the term "product" also encompassing cDNA.

30           Particularly, said method comprises screening for mutations creating cysteine residues in the extracellular or transmembrane domains of the receptor.

Alternatively, or in combination with the foregoing embodiment, it comprises screening for mutations resulting in at least one amino-acid substitution in the kinase domain of the receptor.

35           It particularly comprises screening of activating mutation(s) of *FGFR3*, notably such as above-described.

More particularly, the method of the invention comprises screening for mutation(s) in exon 7, encoding the junction between immunoglobulin-like domains II

and III of FGFR3, in exon 10, encoding the transmembrane domain, in exon 15, encoding the tyrosine kinase domain I, and/or in the exon encoding the C-terminal part.

Advantageously, the method of the invention comprises screening for missense mutations such as implicated in thanatophoric dysplasia, NSC, achondroplasia, saddan, or hypochondroplasia.

Such FGFR3 mutations notably comprise R248C, S249C, G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R, G377C, G382R, A393E, N542K (codons are numbered according to FGFR3-IIIb cDNA open reading frame).

The following FGFR3 mutations will be particularly identified : R248C, S249C, G372C, K652E and Y375C.

Said biological sample used in the method of the invention will advantageously comprise a tissue, bone marrow, or a fluid such as blood, urine, deriving from a warm-blooded animal, and more especially from a human.

Said method is particularly useful for detecting carcinomas, such as human bladder and cervix carcinomas. A major issue in superficial bladder cancer is to distinguish tumours which will progress from those which will not. Insights into the genetic and epigenetic alterations involved in bladder cancer is expected to provide useful information to facilitate this distinction. In that respect, the invention provides means to resolve the dilemma between a bladder-sparing strategy versus cystectomy and will contribute to a more individualised intravesical instillation and endoscopic monitoring policy.

Indeed, as shown by the results given in the examples, *FGFR3* appears to be a major oncogene in Ta, T1 bladder carcinomas. The *FGFR3* mutations appear to be frequently associated with tumours that do not progress. Multivariate analysis showed that *FGFR3* mutation status remained a statistically significant predictor of good outcome. *FGFR3* mutations thus provide clear-cut information, which may complement stage and grade. The use of these mutations alone and/or in combination with other predictors of tumour aggressiveness will then provide relevant prognostic information.

Said method, will also be used for detecting for example lung, breast, colon, skin cancers.

The method of detection according to the invention applies to the diagnostic of carcinomas, as well to the prognosis, or the follow-up of the efficiency of a therapy.

Said method will advantageously be performed by using kits comprising the appropriate reagents and a notice of use.

According to another aspect, the invention relates to drugs having an anti-proliferative effect on carcinoma cells. Such drugs comprise, as active principle(s)

agent(s) which act by inhibition of FGFR3 DNA synthesis or by inhibition of its expression products (RNA, proteins). Particularly, such drugs contain tyrosine kinase inhibitors specific for FGFR3.

Other appropriate inhibitors comprise antibodies directed against FGFR3, and particularly against at least one extracellular Ig-like domain thereof. Advantageously said antibodies are specific for FGFR3-IIIb. Preferred antibodies are monoclonal ones, and particularly antibodies modified so that they do not induce immunogenic reactions in a human body (e.g. humanized antibodies).

Other appropriate inhibitors comprise antisens oligonucleotides directed against a wild or mutated *FGFR3* isoform.

The administration and the posology of said inhibitors will be determined by the one skilled in the art depending on the carcinoma to be treated, the weight and age of the patient. For example, antibodies will be administered by the injectable route.

The invention thus gives means of great interest for detecting and treating carcinomas, taking into account the fact that cancers originating from epithelial tissues (carcinomas) represent approximately 90 % of malignant neoplasms.

The invention also relates to cell lines capable of expressing FGFR3 mutated forms. Particularly, the invention relates to FGFR3 S249C mutated forms. T24 cell lines constitutively expressing FGFR3 S249C mutated forms and HeLa cell lines expressing FGFR3 S249C mutated forms in an inducible manner have thus been obtained (for example see ref.(6)).

By injecting such cell lines to nude mice, an increased tumorigenicity was observed.

According to the invention, such cell lines are useful *in vitro* (follow up of the receptor phosphorylation) or *in vivo* (examination of the tumorigenicity of nude mice) to study the inhibitor effect against FGFR3.

Cell lines transfected with FGFR2, FGFR1 or FGFR4 are particularly useful for studying the specificity of inhibitors to be tested.

According to still another object, the invention relates to constructions capable of expressing by transgenesis a FGFR3 mutated form in epitheliums and the transgenic animals thus obtained which are characterized by the fact that they comprise such constructions.

Examples of constructions intended for injection in animal germinal cells comprise a keratin promoter, particularly keratin 14 promoter and cDNA of mutated FGFR3.

Other advantages and characteristics of the invention will be given in the following examples wherein it will be referred to

- figures 1A - 1B which give FGFR3-IIIb gene activating mutations in primary tumours,

- figures 2A - 2E which refer to FGFR3-IIIb wild (2A) and mutated pro-oncogenic (2B-2T) sequences. It will be noted that the sequences of figures 2B to 2T, as such, enter into the scope of the invention. There may be silent polymorphisms all along the sequence, so there may be in fact several possible sequences for each mutant, and

- figures 3a and 3b which respectively represent a) Kaplan-Meier progression-free survival curves according to *FGFR3* mutations (dotted line: mutated *FGFR3*, solid line: non-mutated *FGFR3*; log rank test  $p=0.014$ ) ; b) Kaplan-Meier disease-specific survival curves according to *FGFR3* mutations (dotted line: mutated *FGFR3*, solid line: non-mutated *FGFR3*; log rank test  $p=0.007$ )

Example 1 : *FGFR3* gene mutations in bladder and cervix carcinomas

*FGFR3-IIIb* and *FGFR3-IIIc* transcript levels were examined by reverse transcription-polymerase chain reaction (RT-PCR) in 76 primary bladder carcinomas and 29 primary invasive cervical carcinomas.

*FGFR3-IIIb*, the sole isoform to be significantly expressed, was detected in 72 out of 76 (94%) bladder carcinomas and 27 out of 29 (93%) cervical carcinomas.

A PCR-SSCP analysis was then conducted on both reverse transcribed RNA and genomic DNA to screen for *FGFR3* coding sequence variants in 26 bladder and 12 cervix cancers expressing the gene. The results are illustrated in figures 1a and 1b which gives the identification of *FGFR3* gene mutations in human carcinomas :

- a: gives the identification of somatic mutations by direct sequencing of PCR products. Normal constitutional DNA ; Tumour, tumour DNA.

- b: gives *FGFR3* mutations associated with skeletal disorders and cancers.

The schematic structure of *FGFR3* is depicted (Ig I-III, immunoglobulin like domains ; TM, transmembrane domain ; TK-1 and -2, tyrosine kinase domains) and the locations of the known human missense mutations associated with thanatophoric dysplasia (TD) and severe achondroplasia (SADDAN), bladder and cervix carcinomas (carc.) and multiple myeloma (MM) are indicated. Usual amino acid abbreviations are used to point out the mutation found in each pathological situation. The mutations at codon 807 incriminated in TD replaces a Stop codon (J) by an amino acid (G, C, R or L) and the mRNA thus continues to be translated until another in-frame Stop codon is reached 423 nucleotides downstream thus leading to a 141 amino acid longer protein.

Abnormally migrating bands were observed for certain samples (Fig. 1a) and direct sequencing of PCR products revealed single nucleotide substitutions in 9 out of 26 bladder carcinomas (35 %) and 3 out of 12 (25 %) cervix carcinomas (Fig. 1b and table 1).

**Table 1**

Summary of FGFR3 gene mutations in primary bladder and cervix cancers					
Sample	Histopathol.	Codon	Nt Position	Mutation	Predicted effect
1447, bladder	carc., Ta G2	249	746	TCC to TGC	Ser to Cys
342, bladder	carc., T1a G1	249	746	TCC to TGC	Ser to Cys
813, bladder	carc., T1a G1	372	1114	GGC to TGC	Gly to Cys
1393.1, bladder	carc., T1a G3	249	746	TCC to TGC	Ser to Cys
506, bladder	carc., T1b G2	372	1114	GGC to TGC	Gly to Cys
1084, bladder	carc., T1b G3	652	1954	AAG to GAG	Lys to Glu
745.1, bladder	carc., T2 G3	248	742	CGC to TGC	Arg to Cys
1077, bladder	carc., T3 G2	249	746	TCC to TGC	Ser to Cys
1210, bladder	carc., T3 G2	249	746	TCC to TGC	Ser to Cys
4.13, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys
4.139, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys
6.96.1, cervix	carc., stage II	249	746	TCC to TGC	Ser to Cys

Histopathol., histopathological classification of the tumours (carc., carcinoma : TNM and HUGO classifications are used respectively for bladder and cervix cancers) ; codon and mutated nucleotide (Nt position) are numbered according to FGFR3-IIIb cDNA open reading frame.

Mutations were found in the following exons

- exon 7, encoding the junction between immunoglobulin-like domains II and III of FGFR3 (one C-to-T transition at codon 248 in patient 745.1 and a C-to-G substitution at codon 249 in patient 1447) ;

- exon 10, encoding the transmembrane domain (a G-to-T-transversion at codon 372 in patient 813)

- exon 15, encoding the tyrosine kinase domain II (a A-to-G transition at codon 652 in patient 1084).

Analysis of matched constitutional DNA from the patients for which such material was available (n=8) demonstrated the somatic nature of these *FGFR3* mutations (Figure 1).

Strikingly, each of the FGFR3 missense mutations identified herein, i.e. R248C, S249C, G372C and K652E, are implicated in thanatophoric dysplasia (TD).

Given the presence of two additional amino-acids in the IIb isoform expressed in epithelial cancers as compared to the IIc isoform expressed in bone, the G372C and K652E mutations are indeed equivalent to the G370C and K650E mutations responsible for TD.

5           The S249C mutation was the most commonly observed, affecting 5 out of 9 (55 %) bladder cancers and all of the cervical cancers (3 out of 3, 100 %) in which *FGFR3* gene alterations have been identified so far.

          The R248C, S249C and G372/370C mutations create cysteine residues in the extracellular or transmembrane domains of the receptor and the K652/650E mutations results in amino-acid substitution in the kinase domain of the receptor.

#### Example 2 : Inhibitors

          A way to test the different *FGFR3* inhibitors comprises transfecting cell lines so that they express the mutated forms of *FGFR3*, or wild type *FGFR3* or just the neomycin or hygromycin resistant gene under the control of a strong promoter, such as CMV, RSV, SV40 promoters. The tumorigenic properties of these cell lines can then be compared *in vitro* or *in vivo* in nude mice. The different inhibitors will be tested *in vitro* or *in vivo* using these different cell lines. Phosphorylation, proliferation or indirect effects of *FGFR3* such as calcium influx will be measured. Transgenic mice expressing in various epithelia the mutated *FGFR3* can thus be derived thereof. Those mice developing tumours are useful tools for testing the efficiency of candidate inhibiting drugs. Such transgenic animals fall also into the scope of the present invention.

#### Example 3 : *FGFR3* mutations in Ta, T1 tumours in bladder cancer.

          Bladder cancer is a disease with a spectrum of forms and is highly unpredictable. At the time of initial diagnosis, approximately 80% of patients present with a superficial tumour. Superficial bladder cancers include carcinoma *in situ* (Tis), Ta and T1 lesions (TNM classification). Ta/T1 lesions are mostly papillary urothelial carcinomas: Ta lesions do not invade the basement membrane, whereas T1 lesions invade the lamina propria, but do not invade the detrusor muscle of the bladder wall. Carcinoma *in situ* are flat, cytologically high-grade carcinomas, confined to the urothelium. Primary isolated carcinoma *in situ* is a very rare entity and is more commonly associated with Ta/T1 lesions. Despite transurethral resection alone or combined with adjuvant intravesical therapies, more than one half of patients with Ta/T1 tumours suffer recurrences. In most cases, recurrences are also superficial, but about 5% of Ta and 30-50% of T1 tumours progress in an unpredictable manner to muscle invasion with a high risk of development of metastases and death from bladder cancer.

          The management of superficial bladder cancer is based on clinicopathological parameters. Three groups of tumours can be defined. of low,

intermediate and high risk, according to their potential for recurrence and progression. This classification is used to recommend adjuvant intravesical therapies and bladder monitoring, but it is not a sufficiently sensitive discriminant for use in determining the appropriate treatment and mode of surveillance for a given patient. Although Bacille Calmette-Guérin (BCG) therapy appeared to be the most effective regimen for the high-risk group, long-term results indicate that progression occurs in 40% by 10 years and in more than 50% by 15 years. For some researchers, these findings justified the use of up-front radical cystectomy in high-risk superficial urothelial carcinomas, despite the risk of overtreating a significant number of patients. Follow-up of Ta and T1 superficial bladder cancers constitutes most of the workload of urologists involved in the management of bladder cancer. The current strategy is based on frequent cystoscopic evaluations using a schedule that is largely empirical, without considering the individual characteristics of the tumour.

The limitations of the current management of bladder cancer demonstrate the need for prognostic markers, making possible the use of selective aggressive treatments for patients at high risk of progression while sparing low-risk patients from unnecessary procedures. A number of chromosomal loci and specific genes have been implicated in bladder tumorigenesis. Losses of all or part of chromosome 9 in many TaG1 tumours suggests that the inactivation of a gene or genes on chromosome 9 may be an early event in urothelial transformation. The prognostic significance of losses on chromosome 9 is unclear. Alterations of the *P53* and *RB* genes controlling the G1 cell cycle checkpoint have been clearly delineated and are associated with the aggressiveness of superficial and invasive bladder cancers. Despite these recent insights into the molecular mechanisms of bladder carcinoma progression, these markers have not yet had any impact on clinical practice.

The following assays have been performed to assess the reliability, as markers, of the FGFR3 mutations.

#### Material and method

##### 30 Patients and tissue samples

Seventy four specimens of superficial Ta, T1 bladder carcinomas were obtained from 74 patients by transurethral resection performed at the Henri Mondor hospital, Créteil, France, from January 1988 to December 1998. Tumours were staged according to the TNM classification (1) and graded according to criteria recommended by the World Health Organisation (2). This series consisted of 25 pTa and 49 pT1 tumours, with 28 grade G1, 33 grade G2 and 13 grade G3 tumours. The 64 men and 10 women had a mean age of 64 years (range: 29 to 94 years). None of the patients had any detectable distant metastases at the time of transurethral resection. Patients were treated

by transurethral resection (TUR) alone (n=25), TUR followed by mitomycin C instillation (n=10) or TUR and BCG (n=39) according to the French Committee for Urologic Oncology (CCAFU) recommendations. There was no change in the policy for treating superficial bladder cancer during the study period. Progression was defined as the occurrence of a pT2 or higher stage or appearance of lymph node invasion or metastasis or death from cancer. Disease-specific survival curves were plotted using death from urothelial cancer as the endpoint. Follow-up was based on systematic cystoscopy and cytology, and imaging studies only when indicated. All outpatient visits and hospital admissions were recorded in a database from which the study data were calculated.

Tumour DNA was extracted from formalin-fixed and paraffin-embedded tissue or samples freshly frozen in liquid nitrogen (4). Normal DNA samples from peripheral blood were available for 27 patients.

#### 15 *FGFR3* mutation analysis

Mutations in the *FGFR3* gene were detected by SSCP analysis. Exons 7, 10, 15 and 20 of the *FGFR3* gene were analysed because these exons harbour all the mutations previously identified in bladder carcinomas and thanatophoric dysplasia. All mutations detected by SSCP analysis were confirmed by direct bidirectional sequencing of tumour genomic DNA. Matched normal DNA, if available, was sequenced on both strands to demonstrate the somatic nature of these mutations.

#### Statistical methods

Associations between *FGFR3* mutation status and other data (sex, age, stage and grade) were tested using  $\chi^2$  and Student's t tests. Progression-free and disease-specific survival curves were plotted using Kaplan-Meier estimates. Survival distributions were compared using the log-rank test. Cox's proportional hazards regression model was used to test the effect of mutations, while simultaneously accounting for baseline patient and tumour characteristics. The influence of the covariates on the *FGFR3* mutation effect was assessed in multivariate analysis involving a forward stepwise procedure and a backward stepwise procedure, using the MPRL (maximum partial likelihood ratio) method. The limit to enter a term was 0.15 and the limit to remove a term was 0.10. Statistical analyses were performed using BMDP® and S-Plus® software.

#### Results

*FGFR3* missense mutations were observed in 41 of the 74 (55%) Ta, T1 bladder tumours. The *FGFR3* mutations found are described in Table 2 below :

Table 2

Number of tumours (%)	Codon*	nt position*	Mutation	Predicted effect
5 (12%)	248	742	CGC -> TGC	Arg -> Cys
28 (68.5%)	249	746	TCC -> TGC	Ser -> Cys
5 (12%)	372	1,114	GGC -> TGC	Gly -> Cys
2 (5%)	375	1,124	TAT -> TGT	Tyr -> Cys
1 (2.5%)	652	1,954	AAG -> GAG	Lys -> Glu

\* codon and mutated nucleotide (nt position) are numbered according to FGFR3-IIIb cDNA open reading frame. FGFR3-IIIb is the isoform expressed in epithelial cells.

5

S249C was the commonest mutation and was found in 16 of the 21 (76%) mutated Ta tumours and 12 of the 20 (60%) mutated T1 tumours. Matched constitutional DNA, available in 15 of the cases of tumour with mutations, contained wild-type sequences, demonstrating the somatic nature of these mutations.

10

The correlation between sex, age, stage, grade and *FGFR3* mutation status is given Table 3 :

Table 3

	<i>FGFR3</i> wild type	<i>FGFR3</i> mutant	p value ( $\chi^2$ or Student's t test)
Sex			
Male	29	35	
Female	4	6	0.9779
Age (years)			
mean	64.30	63.22	
range	[29.15-86.10]	[34.3-94.4]	0.7393
Stage			
Ta	4	21	
T1	29	20	0.001
Grade			
G1	7	21	
G2	14	19	
G3	12	1	0.0003

Statistically significant correlations were observed between *FGFR3* mutations and low stage (p=0.001) and low grade (p=0.0003), but not between these mutations and age or sex (Table 2).

With a median follow-up of 4.3 years (range: 6 months to 11 years), 3 patients progressed and one died in the mutated tumour group (n=41 patients) whereas ten patients progressed and eight died in the non-mutated tumour group (n=33 patients).

The median follow-up was 5.6 years (range: 7 months to 11 years) in the non-mutated group and 4.1 years (range: 6 months to 9 years) in the mutated group.

To examine *FGFR3* mutations as a marker of patient outcome, we calculated Kaplan-Meier progression-free survival and disease-specific survival probability curves for the two groups of patients and examined the differences using the log rank test. Progression-free and disease-specific survival indicated that *FGFR3* mutations were associated with a lower risk of progression ( $p=0.014$ ) and longer survival ( $p=0.007$ ) (Figure 3). We tested several variables (age, sex, stage, grade) but only stage was significantly associated with progression and survival in univariate analysis. If only T1 patients were analysed, the correlation was still significant for disease-specific survival ( $p=0.03$ ) and close to significance for progression-free survival ( $p=0.052$ ).

Multivariate analysis was used to determine whether the correlation between *FGFR3* mutation status and progression-free survival or disease-specific survival was independent of other outcome predictors. For progression-free survival, the following covariates were introduced into the Cox model: mutation, stage, grade and sex. For disease-specific survival, mutation and grade were the only covariates introduced into the model, as no disease-related deaths were observed among female or Ta patients. If *FGFR3* status was entered into the model, neither stage nor grade provided any additional prognostic value for tumour progression. In the analysis of disease-specific survival, *FGFR3* mutation was also the only covariate to be entered into the model, as grade did not provide any additional prognostic information. Relative risks and their 95% confidence intervals (CI) are shown in Table 4.

25

Table 4

	Progression		Disease-specific Survival	
	Relative Risk	95% CI	Relative Risk	95% CI
<i>FGFR3</i>				
Wild-type	1		1	
Mutant	0.23	(0.06; 0.83)	0.10	(0.01; 0.80)
Other variables do not significantly contribute to the model				

Forward and backward procedures both yielded the same model.

As shown by the above results, the FGFR3 activating mutations were frequent in bladder carcinomas.

All the carcinomas having a mutated receptor expressed said receptor at levels similar or above those observed with normal tissues. Immunohistochemical methods will then advantageously be used for revealing the receptor.

FGFR3 mutation detection in bladder carcinomas appears to be a good prognostic, giving then to the clinicians valuable means for treating and observing carcinomas, which represent a medical problem due to the high frequency of recurrences.

By using SSCP or PCR coupled to an enzymatic restriction S249C mutation specific (which represent 75% of the mutations) on patients having bladder carcinomas with S249C mutation, the mutation could be detected in urine in 60% of the cases.

Example 4: Detection of FGFR3 mutations in patients' urines

Genomic DNA is extracted from patients' urines and amplified by PCR, in the presence of <sup>32</sup>P- labelled dCTP, using standard methods. The following primers were used for detecting S249C mutation :

5'-CAG CAC CGC CGT CTG GTT GG-3' and 5'-AGT GGC GGT GGT GGT GAG GGA G-3'.

30 cycles of PCR are performed.

The amplification products are digested by *Cac8I*. An additional site is created by *FGFR3* mutation and a corresponding band is observed on an electrophoretic gel.

Similarly the following primers and enzymes can be used to detect :

R248C mutation :

Primers : 5'-TGT GCG TCA CTG TAC ACC TTG CAG-3' and 5'-AGT GGC GGT GGT GGT GAG GGA G-3'

Enzyme : *Bsi* HKA I

K652E mutation :

Primers : 5'-TGG TGA CCG AGG ACA ACG TGA TG-3' and 5'-AGG GTG TGG GAA GGC GGT GTT G-3'

Enzyme : *Bsm* A I

G372C mutation :

Primers : 5'-CCT CAA CGC CCA TGT CTT TTC AGC-3' and 5'-CTT GAG CGG GAA GCG GGA GAT CTT G-3'

Enzyme : *Pst* I

Y375C mutation :

Primers : 5'-CCT CAA CGC CCA TGT CTT TTC AGC-3' and 5'-CTT GAG CGG  
GAA GCG GGA GAT CTT G-3'

5 Enzyme : *Bsg* I

References

- 5 1. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. *Cancer* 1997; 80: 1803-4.
- 10 2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. *Am J Surg Pathol* 1998; 22: 1435-48.
- 15 3. Rischmann P, Bittard H, Chopin D, et al. Tumeurs Urothéliales. *Prog Urol* 1998; 8: 25-50.
4. Cappellen D, Gil Diez de Medina S, Chopin D, Thiery JP, Radvanyi F. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. *Oncogene* 1997; 14: 3059-66.
- 20 5. Cappellen D, De Oliveira C, Ricol D, Gil Diez de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nature Genetics*, vol 23, sept. 1999.
- 25 6. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracyclines in mammalian cells. *Science* 1995 ; 268 : 1766-9.

CLAIMS

1/ A method for detecting carcinomas in a biological sample, comprising  
5 identifying FGFR3 mutations.

2/ The method of claim 1, comprising screening for single nucleotide  
mutation(s) in nucleic acids of the group comprising genomic DNA, RNA or cDNA.

10 3/ The method of claim 1, comprising screening for single mutation(s) in  
proteins.

4/ The method of claim 1, comprising screening for mutations creating cysteine  
residues in the extracellular or transmembrane domains of the receptor.

15 5/ The method of claim 1, comprising screening for mutations resulting in at  
least one amino-acid substitution in the kinase domain of the receptor.

20 6/ The method of claim 5, comprising screening of activating mutation(s) of  
FGFR3.

7/ The method of claim 6, comprising screening of activating mutation(s) of  
FGFR3-IIIb.

25 8/ The method of claim 1, comprising screening for mutation(s) in the group  
comprising exon 7, encoding the junction between immunoglobulin-like domains II and  
III of FGFR3, exon 10, encoding the transmembrane domain, exon 15, encoding the  
tyrosine kinase domain I, and the exon encoding the C-terminal part.

30 9/ The method of claim 1, comprising screening for missense mutations such as  
implicated in thanatophoric dysplasia, NSC, achondroplasia, SADDAN, or  
hypochondroplasia.

35 10/ The method of claim 9, wherein the mutations comprise R248C, S249C,  
G372C, S373C, Y375C, K652E, K652M, J809G, J809C, J809R, J809L, P250R,  
G377C, G382R, A393E, N542K.

11/ The method of claim 9, comprising screening R248C, S249C, G372C, K652E and Y375C mutations.

5 12/ The method of claim 1, wherein the biological sample is selected in the group comprising a tissue, bone marrow, or a body fluid.

13/ The method of claim 12, wherein said body fluid is selected in the group comprising blood, urine from a warm-blooded animal.

10 14/ The method of claim 13, wherein said body fluid is from a human.

15/ The method of claim 1 for detecting human bladder and cervix carcinomas.

15 16/ The method of claim 1, for detecting lung, breast, colon, skin cancers.

17/ The pharmaceutical preparations having an anti-proliferative effect on carcinoma cells comprising an effective amount of agent(s) which act by inhibition of FGFR3 DNA synthesis or by inhibition of its expression products.

20 18/ The pharmaceutical preparations of claim 17, comprising tyrosine kinase inhibitors specific for FGFR3.

19/ The pharmaceutical preparation of claim 18, comprising antibodies directed againstp FGFR3.

25 20/ The pharmaceutical preparations of claim 17, comprising antisens oligonucleotides directed against a wild type or mutated FGFR3 isoform.

1/22

FIGURE 1





Figure 2A

Wild Type FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCTCGTGGGGCGAGCGGCAGAAAGTCCCGGGCCCGAGGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCAGTGGAGGCGATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCTGCAAGGTGTACAGTACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCAGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCCTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCCT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGGCGCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGGC  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGCATGGAGTACTTGGCCTCCAGA  
AGTGCATCCACAGGGACCTGGCTGCCCCGAATGTGTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTGTGACCGAGTCTACACTCACCAGAGTGACGTCTGTCTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCGCAAC  
TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCC  
CGGGTGGCCAGGACACCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGTGCCCCGGGCCCA  
CCAGCAGTGGGGCTCGCGGACGTGA

Figure 2B

Mutant R248C FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGTGGAGTGTCCCCGACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCTACGTTACCGTGTCAAGTCTTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCGCTGGCCAATGTGTGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCCTTTTGGCTGAGCGTTACAGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGACGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCCCCAAGAAAGGCTGGGCTCCCCACCGTGACAAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGTCACTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGATGGAGTACTTGGCCTCCAGAG  
AGTGCATCCACAGGGACCTGGCTGCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCGGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2c

Mutant S249C FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCTCGTGGGGCGAGCGGCAGAACTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCGCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGTACGCGAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCGGGCCGCCAACCCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAAGCGCAGGGAGTTCCGCGGGCAGCACCCGATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTGCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCGGACGGCACACCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACCGGGCCCCGAGCAGCCGAGGAGAGCTGGTGGAGGCTGACGAGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGACAAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGA  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTGACCGAGTCTACACTACCCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCCAGCTCCAGCTCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2D

Mutant G372C FGFR3-IIIb:

ATGGGGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGGCCAGAGCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACAGGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCSCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAGCGTGGTGCCTCGGACCGCGGCACTACACCTGCGTGGTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGAGCTGTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGAGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCGGACGGCACACCTACGTTACCGTGTCAAGTCTTGATCAGTGAGAGTGTGGAGGCGGAC  
GTGCGCTCCGCTGGCCAATGTGTGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGTGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTCTGCGGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCAACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA  
AGTGCATCCACAGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGTCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGGCCCA  
CCCAGCAGTGGGGGCTCGCGGACGTGA

6/22

Figure 2E

Mutant K652E FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCCTCGGAGCGTGTCTGTGGGGCCCGAGCGGTGCAGGTGCTGAATGCCTCCACAGGAGTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCAGCATTTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCCATCCTGCAGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCAGGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGGCCGAC  
GTGCGCCTCCGCCTGGCCAATGTGTGCGGAGCGGGACGGGGCGAGTACCTCTGTGAGGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCTGGGCTCCCCCACCCTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCT  
GGGAGGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACAGGTGGCCCGGGGATGGAGTACTTGGCCTCCAGAG  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGGAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGCCACGACCTGCTGCCCGGGCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2F

Mutant S373C FGFR3-IIb:

ATGGGCGCCCTGCTGCGCCCTCGCGCTCTGCGTGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAACTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGTCCGGGGCCTA  
CAGTGGCGGCGAGCGGCTCAGCGAGCGGTAAGTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCGGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGGCGGGCAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTGTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCGGACGGCACACCTACGTTACCGTGTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACCGGGCCCCGAGCAGCGGAGGAGCTGGTGGAGGCTGACGAGCGGGGCTGTG  
TGTATGACGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGTCTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACAGGTGGCCCGGGGCGATGGAGTACTTGGCCTCCAGGA  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGG  
GCTCCCCGTACCCCGGCATCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

8/22

Figure 2G

Mutant Y375C FGFR3-IIIB:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCSTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGTTGGGGCCCGAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCCGGGCGAGCACCGCATTTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCGCACCGGCCCATCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCAACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCTACGTACCGTGTCAAGTCTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCTGGCCAATGTGTGCGGACGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTGTGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGCCCCGGGGCATGGAGTACTTGGCCTCCCAGA  
AGTGATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGACACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

9/22

Figure 2H

Mutant K652M FGFR3-IIb:

ATGGGGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCGGGCCGCAACACCGTCCGCTTCGCGTGGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGGCAGCACCCGATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGAGCTGTGGAGCGCTCCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGCAGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCTACGTTACCGTGTCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTCGCCAATGTGTGCGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT  
AGCCSTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGGGCGGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACAGGTGGCCCGGGGCGATGGAGTACTTGGCCTCCCAGA  
AGTGATCCACAGGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGATGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGGCCCCA  
CCCAGCAGTGGGGGCTCGCGGACGTGA

10/22

Figure 2I

Mutant X809C FGFR3-IIIb:

ATGGGCGCCCTGCCTGCCCTCGCGCTCTGCGTGGCCGTGGCCATCSTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGTCCCGGGCCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTGCTCAAGTCCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGTGGGCTTCTTCTGTTTATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAAGTGGCCCGGGGCATGGAGTACTTGGCTTCCAG  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTGTGACCGAGTCTACACTCACCAGAGTGACGTCTGCTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGC

11/22

Figure 2J Mutant 1

Mutant X809G FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGCATGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGTGGAGCGCTCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCCCTACGTTACCGTGCTCAAGTCTTGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGCCCGGAGCAGCCGAGGAGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCCT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGAG  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCCAGCAGTGGGGGCTCGCGGACGGGA

12/22

Figure 2K Mutant 2

Mutant: X809G FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCTCGGAGCGTGTCTGTTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGCATTTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCTCGGACCGCGGCAACTACACCTGCGCTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCTGGCCAATGTGTCGGAGCGGGACGGGGGGCAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGACAAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCAGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCCT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGGCGATGGAGTACTTGGCCTCCAGAG  
AGTGCAATCCACAGGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGCGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCGCGGCCCA  
CCCAGCAGTGGGGGCTCGCGGACGAGA

Figure 2L Mutant 3

Mutant X809G FGFR3-IIib:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTTGGGGCGAGCGGCAGAAAGTCCCGGGCCCGAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGCATTGGAGGCATCAAGCTGCCGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCGCACCAGGCCCATCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCGGACGGCACACCTACGTTACCGTGTCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCTGGCCAAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACAGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCCTGCACAAGATCTCCGCTTCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTCAATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGAG  
AGTGCATCCACAGGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCGGGACGTGCAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCCGGCCCA  
CCAGCAGTGGGGGCTCGCGGACGCGA

Figure 2M

Mutant X909L FGFR3-IIIB:

ATGGGCGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGCCGCTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGCTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACCCGTCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCGCACCCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCGAGCGAGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCCGGACGGCACACCTAGGTTACCGTGCTCAAGTCCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGGCCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA  
AGTGCATCCACAGGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTCTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCCGCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTTA

Figure 2N Mutant 1

Mutant N542K FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGCCGCGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTGGGCGAGCGGCAGAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCAGCGAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCGGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAAGCGTGGTGCCTCGGACCGCGGCCAATAACCTGCGTCTGGAGAACAAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCCGGCCATCCTGCAGGCGGGGCTGCCGGCCAAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCCCTACGTTACCGTGCTCAAGTCTTGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTCGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGACAAGATCTCCCGCTTCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCGAGCTCGAGCTGCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTTGGGCAAGCCCCCT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAAACCTGCTGGGCGCCTGCACGAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCA  
AGTGATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTTCAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGCTCGCGGACGTGA

16/22

Figure 20 Mutant 2

Mutant N542K EGFR3-IIIB:

ATGGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCCTGGCCATCGTGGCCGGCGCCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCCTCGGAGCGTGTCTGTGGGGCCCGAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGTCCGGGGCCCTA  
CAGCTGCCGGCAGCGGCTCACGCGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCTTACTGGACACGGGCCGAGCGGATGGAC  
AAGAAGCTGCTGGCGGTGCCGGCCGCCAACCCGTCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTCAGGAGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTGGTGGAGAACAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCGGCCCATCTGCAGGCGGGGCTGCCGGCCAAACCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCTACTGCAAGGTGTACAGTGACGCACAGCCCAACATCCAGTGGCTCAAGCAGCTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCCGACGGCACACCCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCATGTGTGGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCCTTTGGCTGAGCGTTACCGGGCCCCGAGCAGCGGAGGAGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGACGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTCATCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCGCTTCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCGGGCCCGGCTGACCCCTGGGCAAGCCCTT  
CCAATGTCTCCGAGCTCGAGCTGCCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCCTGGGCAAGCCCTT  
GGGGAGGCTGCTTGGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAAGCTGCTGGGGCGCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGGCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCGAGA  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACACAGTGAAGATCGCAGACTTCGGGCTG  
GCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTGTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCGAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCAGACCTGCTGCCCCGGCCCCA  
CCCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2P Mutant 1

Mutant G382R FGFR3-IIIb:

ATGGGCGCCCCCTGCCTGCGCCCTCGCGCTCTGCGTGCCCGTGCCCATCGTGCCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCCTTACTGGACACGGCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGACCCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAAACCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGCACGACAGCCACATCCAGTGGCTCAAGCAGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGACAGGCATCCTCAGCTACAGGCTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGGCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCTCCCAGA  
AGTGCATCCACAGGGACCTGGCTGCGCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCCTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCCGGCCCA  
CCAGCAGTGGGGCTCGCGGACGTGA

Figure 2Q Mutant 2

Mutant G382R FGFR3-IIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCTGCTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCGAGTGTGAATGCCTCCACAGGAGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACGCGATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGGCCGGACGGCACACCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTCGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGCCCCGAGCAGCCGAGGAGGAGTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGATGCAGGCATCCTCAGCTACCGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCTGGGCTCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACCGCTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGCGGGCCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCGA  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCTGAGGC  
CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGG  
GCTCCCCGTACCCCGCATCCCTGTGGAGGAGTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGTGGT  
GGAGGACCTGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACCCCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2R

Mutant G377C FGFR3-IIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGGCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGGCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGGTCCCGGCCAACCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCCGACGGCACACCCTACGTTACCGTGCTCAAGTCCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAAATGTGTGCGAGCGGGACGGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCATGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGCACAAGATCTCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAAGGCGGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGGCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA  
AGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

20/22

Figure 25

Mutant A393E FGFR3-IIIb:

ATGGGCGCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCTGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCGCCCCGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGG  
CTGGTGCCCTCGGAGCGTGTCTGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACGAGGACTCCGGGGCCTA  
CAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGCCTCGGACCGCGGCAACTACACCTGCGTCTGGGAGAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCATCCTGCAGGCGGGGCTGCCGGCCAACAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGCCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCTCCGCCTGGCCAATGTGTCGGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTACGGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGAGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCACCGTGACACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTACCCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCTGGACTACTCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCAGA  
AGTGATCCACAGGGACCTGGCTGCCCCGAATGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTGTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTCACGCTGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCAGAGGCCACCTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGCGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGCCCCA  
CCAGCAGTGGGGGCTCGCGGACGTGA

Figure 2f

Mutant P250R FGFR3-IIIb:

ATGGGGCGCCCTGCTGCGCCCTCGCGCTCTGCGTGCCGTGGCCATCGTGCCGCGCGCTCCTCGGAGTCCTTGGGGAC  
GGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAAGTCCCGGGCCAGAGCCCGCCAGCAGGAGCAGTTGGTCTTCGGCAGCG  
GGGATGCTGTGGAGCTGAGCTGTCCCCCGCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGGCAGAGG  
CTGGTGGCCCTCGGAGCGTGTCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCACAGGAGTCCCGGGCCCTA  
CAGCTGCCCGCAGCGGCTCACGCAGCGCTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATG  
ACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCCTTACTGGACACGGCCCGAGCGGATGGAC  
AAGAAGCTGCTGGCCGTGCGGGCCGCAACACCGTCCGCTTCCGCTGCCAGCCGCTGGCAACCCCACTCCCTCCATCTC  
CTGGCTGAAGAACGGCAGGGAGTTCGCGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGG  
TCATGGAAAGCGTGGTGGCCCTCGGACCGGGCAACTACACCTGCGTCTGGAGAAACAAGTTTGGCAGCATCCGGCAGACG  
TACACGCTGGACGTGCTGGAGCGCTCCCGGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCAACCCAGACGGCGGTGCT  
GGGCAGCGACGTGGAGTTCACCTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGA  
ACGGCAGCAAGGTGGGCCCGGACGGCACACCTACGTTACCGTGCTCAAGTCTGGATCAGTGAGAGTGTGGAGGCCGAC  
GTGCGCCTCCGCTGGCCAATGTGTGCGAGCGGGACGGGGCGAGTACCTCTGTGAGCCACCAATTTTCATAGGCGTGGC  
CGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTG  
TGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCTGTTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCTG  
CGCAGCCCCCAAGAAAGGCCTGGGCTCCCCCACCCTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCT  
GGAGTCCAACCGCTCCATGAGCTCCAACACACCACTGGTGGCATCGCAAGGCTGTCTCAGGGGAGGGCCCCACGCTGG  
CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCTGGGCAAGCCCCCTT  
GGGGAGGGCTGCTTCGGCCAGGTGGTTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCAAGCCTGTACCGT  
AGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGTGCGACCTGGTGTCTGAGATGGAGATGATGAAGATGA  
TCGGGAAACACAAAACATCATCAACTGCTGGCGCCTGCACGCAGGGCGGGGCCCTGTACGTGCTGGTGGAGTACGCG  
GCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGGCCCCCGGGCTGGACTACTCCTTCGACACCTGCAAGCCGCC  
CGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCTGTGCTTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGA  
AGTGATCCACAGGGACCTGGCTGCCGCAATGTGTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTG  
GCCCCGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGC  
CTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGGTCTTTGGGGTCTGCTCTGGGAGATCTTACGCTGGGGG  
GCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAAC  
TGCACACACGACCTGTACATGATCATGCGGGAGTGTGGCATGCCGCGCCCTCCAGAGGCCCACTTCAAGCAGCTGGT  
GGAGGACCTGGACCGTGTCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTGGCGCCTTTCGAGCAGTACTCCC  
CGGGTGGCCAGGACACCCCAAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTGCCACGACCTGCTGCCCCGGCCCCA  
CCCAGCAGTGGGGGCTCGCGGACGTGA

22/22

FIGURE 3

